Repaglinide | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Repaglinide
Health Canada Patents

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Repaglinide

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

26 API Suppliers, 12 USDMF, 11 CEP/COS, 3 JDMF, 8 EU WC, 2 KDMF, 8 NDC API, 17 Listed Suppliers, $ API Reference Price

26 API Suppliers
12 USDMF
11 CEP/COS
3 JDMF
8 EU WC
2 KDMF
8 NDC API
17 Listed Suppliers
$ API Reference Price

INTERMEDIATES

5 Intermediate Suppliers

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

262 FDF Dossiers, 31 FDA Orange Book, 191 Europe, 15 Canada, 3 South Africa, 22 Listed Dossiers

262 FDF Dossiers
31 FDA Orange Book
191 Europe
15 Canada
3 South Africa
22 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 500MG;1MG, TABLET;ORAL - 500MG;2MG

TABLET;ORAL - 0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 500MG;1MG
TABLET;ORAL - 500MG;2MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Rochem International Inc, 6 SPI Pharma, 2 Seqens, 3 DKSH, 5 Faran Shimi Pharmaceutical, 4 Boai NKY Pharmaceuticals Ltd, 5 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 5 Actylis, 1 Aeon Procare, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 27 BASF, 1 Corel Pharma Chem, 3 DFE Pharma, 1 Doshion Polyscience, 2 Finar, 9 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 3 Ingredion Pharma Solutions, 5 Kerry, 8 Microlex e.U, 2 Nanjing Bold Chemical, 2 Nomisma Healthcare, 1 Novo Excipients, 2 Pharmatrans-Sanaq, 6 Pluviaendo, 3 Prachin Chemical, 25 Roquette, 1 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 1 Ulanqab Kema New Material, 2 Valens Pharmachem, 3 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

46 Fillers, Diluents & Binders, 22 Direct Compression, 20 Thickeners and Stabilizers, 20 Disintegrants & Superdisintegrants, 20 Granulation, 19 Solubilizers, 16 Lubricants & Glidants, 16 Film Formers & Plasticizers, 16 Topical, 15 Coating Systems & Additives, 15 Taste Masking, 14 Controlled & Modified Release, 13 Parenteral, 11 Co-Processed Excipients, 8 Chewable & Orodispersible Aids, 5 Emulsifying Agents, 2 API Stability Enhancers, 2 Coloring Agents, 2 Rheology Modifiers, 1 Soft Gelatin, 1 Surfactant & Foaming Agents

46 Fillers, Diluents & Binders
22 Direct Compression
20 Thickeners and Stabilizers
20 Disintegrants & Superdisintegrants
20 Granulation
19 Solubilizers
16 Lubricants & Glidants
16 Film Formers & Plasticizers
16 Topical
15 Coating Systems & Additives
15 Taste Masking
14 Controlled & Modified Release
13 Parenteral
11 Co-Processed Excipients
8 Chewable & Orodispersible Aids
5 Emulsifying Agents
2 API Stability Enhancers
2 Coloring Agents
2 Rheology Modifiers
1 Soft Gelatin
1 Surfactant & Foaming Agents

DIGITAL CONTENT

8 NEWS #PharmaBuzz

8 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 155 Finished Drug Prices, 5 Annual Reports

1 US Medicaid Prescriptions
155 Finished Drug Prices
5 Annual Reports

MARKET PLACE

7 APIs, 2 FDF Dossiers

7 APIs
2 FDF Dossiers

PATENTS & EXCLUSIVITIES

6 Health Canada Patents

6 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 1 USP, 5 Others

3 EDQM
1 USP
5 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 2,531 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

6 All

01 3Novo Nordisk Canada Inc.

02 3Blank

filter Patent Reset all filters

6 All

01 31225398

02 32111851

filter Product Reset all filters

6 All

01 3Repaglinide

02 3Blank

filter Dosage Reset all filters

6 All

01 3Tablet

02 3Blank

filter Exp Date Reset all filters

6 All

01 32004-08-11

02 32011-06-21

Product Main Page

01

Novo Nordisk Canada Inc.

Repaglinide

BioAsia

Not Confirmed

Novo Nordisk Canada Inc.

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2011-06-21

Date Granted : 2002-02-26

Repaglinide

Brand Name : GLUCONORM

Patent Number : 2111851

Filing Date : 1991-06-21

Strength per Unit : 0.5mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2011-06-21

Date Granted : 2002-02-26

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Novo Nordisk Canada Inc.

Repaglinide

BioAsia

Not Confirmed

Novo Nordisk Canada Inc.

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2011-06-21

Date Granted : 2002-02-26

Repaglinide

Brand Name : GLUCONORM

Patent Number : 2111851

Filing Date : 1991-06-21

Strength per Unit : 1.0mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2011-06-21

Date Granted : 2002-02-26

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Novo Nordisk Canada Inc.

Repaglinide

BioAsia

Not Confirmed

Novo Nordisk Canada Inc.

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2011-06-21

Date Granted : 2002-02-26

Repaglinide

Brand Name : GLUCONORM

Patent Number : 2111851

Filing Date : 1991-06-21

Strength per Unit : 2.0mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2011-06-21

Date Granted : 2002-02-26

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Repaglinide

BioAsia

Not Confirmed

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2004-08-11

Date Granted :

Repaglinide

Brand Name :

Patent Number : 1225398

Filing Date :

Strength per Unit :

Dosage Form :

Human Or VET :

Route of Administration :

Patent Expiration Date : 2004-08-11

Date Granted :

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

Repaglinide

BioAsia

Not Confirmed

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2004-08-11

Date Granted :

Repaglinide

Brand Name :

Patent Number : 1225398

Filing Date :

Strength per Unit :

Dosage Form :

Human Or VET :

Route of Administration :

Patent Expiration Date : 2004-08-11

Date Granted :

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

06

Repaglinide

BioAsia

Not Confirmed

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2004-08-11

Date Granted :

Repaglinide

Brand Name :

Patent Number : 1225398

Filing Date :

Strength per Unit :

Dosage Form :

Human Or VET :

Route of Administration :

Patent Expiration Date : 2004-08-11

Date Granted :

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!